Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod + Tofacitinib in csDMARD-IR Rheumatoid Arthritis
NCT05803135Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of iguratimod in rheumatoid arthritis (RA), sponsored by Nanfang Hospital, Southern Medical University. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
iguratimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05803135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803135.